INTRODUCTION: Malaria is a major health problem in the tropics, with 300-500 million new clinical cases annually, most of them cases of uncomplicated malaria. An estimated 1.1-2.7 million deaths occur annually as a result of severe falciparum malaria. Uncomplicated malaria can progress to severe malaria, become chronic, or resolve, depending on host immunity and prompt access to appropriate treatment. METHODS AND OUTCOMES: We conducted a systematic review and aimed to answer the following clinical questions: Are artemisinin combination treatments more effective than non-artemisinin combination treatments in people living in endemic areas (excluding South East Asia)? Which artemisinin combination treatment is most effective in people living in endemic areas? We searched: Medline, Embase, The Cochrane Library and other important databases up to November 2006 (Clinical Evidence reviews are updated periodically, please check our website for the most up-to-date version of this review). We included harms alerts from relevant organisations such as the US Food and Drug Administration (FDA) and the UK Medicines and Healthcare products Regulatory Agency (MHRA). RESULTS: We found 18 systematic reviews, RCTs, or observational studies that met our inclusion criteria. We performed a GRADE evaluation of the quality of evidence for interventions. CONCLUSIONS: In this systematic review we present information relating to the effectiveness and safety of the following interventions: amodiaquine plus sulfadoxine-pyrimethamine, artemether-lumefantrine, artesunate plus mefloquine, artesunate plus amodiaquine, and artesunate plus sulfadoxine.
INTRODUCTION:Malaria is a major health problem in the tropics, with 300-500 million new clinical cases annually, most of them cases of uncomplicated malaria. An estimated 1.1-2.7 million deaths occur annually as a result of severe falciparum malaria. Uncomplicated malaria can progress to severe malaria, become chronic, or resolve, depending on host immunity and prompt access to appropriate treatment. METHODS AND OUTCOMES: We conducted a systematic review and aimed to answer the following clinical questions: Are artemisinin combination treatments more effective than non-artemisinin combination treatments in people living in endemic areas (excluding South East Asia)? Which artemisinin combination treatment is most effective in people living in endemic areas? We searched: Medline, Embase, The Cochrane Library and other important databases up to November 2006 (Clinical Evidence reviews are updated periodically, please check our website for the most up-to-date version of this review). We included harms alerts from relevant organisations such as the US Food and Drug Administration (FDA) and the UK Medicines and Healthcare products Regulatory Agency (MHRA). RESULTS: We found 18 systematic reviews, RCTs, or observational studies that met our inclusion criteria. We performed a GRADE evaluation of the quality of evidence for interventions. CONCLUSIONS: In this systematic review we present information relating to the effectiveness and safety of the following interventions: amodiaquine plus sulfadoxine-pyrimethamine, artemether-lumefantrine, artesunate plus mefloquine, artesunate plus amodiaquine, and artesunate plus sulfadoxine.
Authors: Charles O Obonyo; Elizabeth A Juma; Bernhards R Ogutu; John M Vulule; Joseph Lau Journal: Trans R Soc Trop Med Hyg Date: 2006-09-15 Impact factor: 2.184
Authors: Corine Karema; Caterina I Fanello; Chantal van Overmeir; Jean-Pierre van Geertruyden; Walli van Doren; Daniel Ngamije; Umberto D'Alessandro Journal: Trans R Soc Trop Med Hyg Date: 2006-06-12 Impact factor: 2.184
Authors: C I Fanello; C Karema; W van Doren; Chantal Van Overmeir; D Ngamije; U D'Alessandro Journal: Trans R Soc Trop Med Hyg Date: 2006-09-26 Impact factor: 2.184
Authors: Frank P Mockenhaupt; Stephan Ehrhardt; Stephen Y Dzisi; J Teun Bousema; Nasstasja Wassilew; Jonas Schreiber; Sylvester D Anemana; Jakob P Cramer; Rowland N Otchwemah; Robert W Sauerwein; Teunis A Eggelte; Ulrich Bienzle Journal: Trop Med Int Health Date: 2005-06 Impact factor: 2.622
Authors: Robert Hutagalung; Lucy Paiphun; Elizabeth A Ashley; Rose McGready; Alan Brockman; Kaw L Thwai; Pratap Singhasivanon; Thomas Jelinek; Nicholas J White; François H Nosten Journal: Malar J Date: 2005-09-22 Impact factor: 2.979
Authors: Ingrid van den Broek; Christa Kitz; Sarwatt Al Attas; François Libama; Manica Balasegaram; Jean-Paul Guthmann Journal: Malar J Date: 2006-11-24 Impact factor: 2.979
Authors: Ingrid van den Broek; Ribka Amsalu; Manica Balasegaram; Pamela Hepple; Engudaye Alemu; El Badri Hussein; Muhammed Al-Faith; Jacqui Montgomery; Francesco Checchi Journal: Malar J Date: 2005-02-24 Impact factor: 2.979
Authors: Ebtihal A Mukhtar; Nahla B Gadalla; Salah-Eldin G El-Zaki; Izdihar Mukhtar; Fathi A Mansour; Ahmed Babiker; Badria B El-Sayed Journal: Malar J Date: 2007-07-15 Impact factor: 2.979
Authors: Alejandro Llanos-Cuentas; Martin Casapia; Raúl Chuquiyauri; Juan-Carlos Hinojosa; Nicola Kerr; Maria Rosario; Stephen Toovey; Robert H Arch; Margaret A Phillips; Felix D Rozenberg; Jade Bath; Caroline L Ng; Annie N Cowell; Elizabeth A Winzeler; David A Fidock; Mark Baker; Jörg J Möhrle; Rob Hooft van Huijsduijnen; Nathalie Gobeau; Nada Araeipour; Nicole Andenmatten; Thomas Rückle; Stephan Duparc Journal: Lancet Infect Dis Date: 2018-06-13 Impact factor: 25.071